Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML)
Open Access
- 13 February 2008
- journal article
- research article
- Published by Springer Nature in BMC Cancer
- Vol. 8 (1) , 51
- https://doi.org/10.1186/1471-2407-8-51
Abstract
Chemotherapeutic drug efflux via the P-glycoprotein (P-gp) transporter encoded by the MDR1/ABCB1 gene is a significant cause of drug resistance in numerous malignancies, including acute leukemias, especially in older patients with acute myeloid leukemia (AML). Therefore, the P-gp modulators that block P-gp-mediated drug efflux have been developed, and used in combination with standard chemotherapy. In this paper, the capacity of zosuquidar, a specific P-gp modulator, to reverse chemoresistance was examined in both leukemia cell lines and primary AML blasts.Keywords
This publication has 24 references indexed in Scilit:
- Phase I/II trial of a P-glycoprotein inhibitor, Zosuquidar.3HCl trihydrochloride (LY335979), given orally in combination with the CHOP regimen in patients with non-Hodgkin's lymphomaLeukemia & Lymphoma, 2007
- Controversies in Treatment of AML: Case-based DiscussionHematology-American Society Hematology Education Program, 2006
- The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosisBlood, 2005
- New Strategies for the Treatment of Acute Myeloid Leukemia Including Antibodies and Other Novel AgentsHematology-American Society Hematology Education Program, 2005
- Dose Escalation Studies of Cytarabine, Daunorubicin, and Etoposide With and Without Multidrug Resistance Modulation With PSC-833 in Untreated Adults With Acute Myeloid Leukemia Younger Than 60 Years: Final Induction Results of Cancer and Leukemia Group B Study 9621Journal of Clinical Oncology, 2004
- A Phase I Trial of a Potent P-Glycoprotein Inhibitor, Zosuquidar Trihydrochloride (LY335979), Administered Intravenously in Combination with Doxorubicin in Patients with Advanced MalignancyClinical Cancer Research, 2004
- ABCG2 – a transporter for all seasonsFEBS Letters, 2004
- Multidrug resistance protein attenuates gemtuzumab ozogamicin–induced cytotoxicity in acute myeloid leukemia cellsBlood, 2003
- Modulation of P‐glycoprotein but not MRP1‐ or BCRP‐mediated drug resistance by LY335979International Journal of Cancer, 2002
- Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemiaThe Hematology Journal, 2000